Claudia Lobato da Silva
Overview
Explore the profile of Claudia Lobato da Silva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
934
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Branco A, Bucar S, Moura-Sampaio J, Lilaia C, Cabral J, Fernandes-Platzgummer A, et al.
Front Bioeng Biotechnol
. 2020 Dec;
8:573282.
PMID: 33330414
Umbilical cord blood (UCB) has been established as an alternative source for hematopoietic stem/progenitor cells (HSPC) for cell and gene therapies. Limited cell yields of UCB units have been tackled...
2.
Fuzeta M, Bernardes N, Oliveira F, Costa A, Fernandes-Platzgummer A, Farinha J, et al.
Front Cell Dev Biol
. 2020 Nov;
8:553444.
PMID: 33224943
Mesenchymal stromal cells (MSC) hold great promise for tissue engineering and cell-based therapies due to their multilineage differentiation potential and intrinsic immunomodulatory and trophic activities. Over the past years, increasing...
3.
Cabral J, Lobato da Silva C, Diogo M
Bioengineering (Basel)
. 2020 Aug;
7(3).
PMID: 32751782
The next healthcare revolution will apply regenerative medicines using human cells and tissues [...].
4.
de Sousa Pinto D, Bandeiras C, Fuzeta M, Rodrigues C, Jung S, Hashimura Y, et al.
Biotechnol J
. 2020 Aug;
15(8):e2070064.
PMID: 32749078
No abstract available.
5.
Silva M, Monteiro G, Fialho A, Bernardes N, Lobato da Silva C
Front Cell Dev Biol
. 2020 Aug;
8:471.
PMID: 32733876
Recently, cell-based therapies have been explored as a strategy to enhance the specificity of anticancer therapeutic agents. In this perspective, human mesenchymal stromal cells (MSC) hold a promising future as...
6.
Fernandes-Platzgummer A, Andrade P, Cabral J, Lobato da Silva C
Methods Mol Biol
. 2020 Jun;
2286:107-120.
PMID: 32488668
In the context of hematopoietic cell transplantation, hematopoietic stem/progenitor cells (HSPC) from the umbilical cord blood (UCB) present several advantages compared to adult sources including higher proliferative capacity, abundant availability...
7.
Moura C, Silva J, Faria S, Fernandes P, Lobato da Silva C, Cabral J, et al.
J Biosci Bioeng
. 2020 Feb;
129(6):756-764.
PMID: 32107152
Cartilage defects resultant from trauma or degenerative diseases (e.g., osteoarthritis) can potentially be repaired using tissue engineering (TE) strategies combining progenitor cells, biomaterial scaffolds and bio-physical/chemical cues. This work examines...
8.
Fuzeta M, Branco A, Fernandes-Platzgummer A, Lobato da Silva C, Cabral J
Adv Biochem Eng Biotechnol
. 2019 Dec;
171:225-278.
PMID: 31844924
Exciting developments in the cell therapy field over the last decades have led to an increasing number of clinical trials and the first cell products receiving marketing authorization. In spite...
9.
de Sousa Pinto D, Bandeiras C, Fuzeta M, Rodrigues C, Jung S, Hashimura Y, et al.
Biotechnol J
. 2019 Apr;
14(8):e1800716.
PMID: 30945467
Mesenchymal stromal cells (MSC) hold great promise for tissue engineering applications and cell-based therapies. Large cell doses (>1 × 10 cells kg ) and Good Manufacturing Practices (GMP)-compliant processes are...
10.
Fernandes-Platzgummer A, Carmelo J, Lobato da Silva C, Cabral J
Methods Mol Biol
. 2016 May;
1416:375-88.
PMID: 27236684
The therapeutic potential of mesenchymal stem/stromal cells (MSC) has triggered the need for high cell doses in a vast number of clinical applications. This demand requires the development of good...